BeijngFH Health Cohort Study

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

NCT Number	NCT05546086
Lead Sponsor	Beijing Friendship Hospital Collaborators: Chinese Academy of Medical Sciences
Conditions	Non-Alcoholic Fatty Liver Disease
Enrollment	8,103 participants
Start Date	2022-04-18
Primary Completion	2032-04-18 (estimated)
Study Completion	2032-04-18 (estimated)
Updated on ClinicalTrials.gov	2022-09-21